Clinical trials: Survival , Tumor
Esophageal Cancer
Design of the EFECTS Trial
It is well known that there is a considerable postoperative weight loss in patients undergoing esophageal resection for cancer. We believe that this weigh loss can be limited by administering postoperative enteral feeding…
- Trial name
- EFECTS (NCT02017366)
- Testing
- Enteral feeding
- Where
- Belgium
- Sponsor
- University Hospital, Gasthuisberg
Lung Cancer, Gene Abnormality
iCAGES-guided Precision Therapy for Cancers in Contrast to Standard Care or IHC-guided Theray
This study prospectively evaluates whether the use of iCAGES (integrated CAncer GEnome Score) tool in guiding the treatment of advanced cancers is superior to current standard care or IHC-guided therapy in progress free survival…
- Conditions
- Lung Cancer, Gene Abnormality, Gene Product Sequence Variation, Cancer
- Trial name
- NCT03192501
- Testing
- inhibitors, ADC drugs such as tarceva, capmatinib, padcev et al for A/C group.
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) in Sequential Combination With Gemcitabine as First Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer
This 2 arm study will compare the efficacy and safety of sequential treatment with Tarceva and gemcitabine, and of gemcitabine monotherapy, as first line treatment of elderly patients, or patients with ECOG performance status of…
- Trial name
- NCT00940875
- Testing
- erlotinib [Tarceva], gemcitabine
- Where
- 17 sites in Australia
- Volunteers
- 54 people
- Sponsor
- Hoffmann-La Roche
Hepatocellular Carcinoma
Transarterial Chemoembolization Prior to Transplantation for Hepatocellular Carcinoma
The hope to treat more patients with hepatocellular carcinoma successfully is however tempered by the shortage of donors leading to an increasing waiting time for liver transplantation (LT).
- Trial name
- CATCH (NCT01676194)
- Testing
- Intra-arterial administration of DC BeadsR
- Where
- 7 sites in France
- Volunteers
- 7 people
- Sponsor
- Rennes University Hospital
Histologic Response (Tumor Necrosis Rate), Objective Response Rate for Neoadjuvant Chemotherapy, ORR
Epigenetic Biomarker for Osteosarcoma
hMe-Seal is a low-input whole-genome cell-free 5hmC sequencing method based on selective chemical labeling. It uses β-glucosyltransferase (βGT) to selectively label 5hmC with a biotin via an azide-modified glucose for pull-down…
- Conditions
- Histologic Response (Tumor Necrosis Rate), Objective Response Rate for Neoadjuvant Chemotherapy, ORR, Progression-free Survival, PFS, Overall Survival, OS
- Trial name
- NCT03336554
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
Unresectable Gastrointestinal Stromal Tumor (GIST), Locally Advanced Gastrointestinal Stromal Tumor (GIST)
A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments
This trial is a prospective, randomized (1:1 ratio), multicenter, comparative and phase II study, conducted in patients with unresectable advanced gastrointestinal stromal tumors (GIST) after failure of imatinib (disease…
- Conditions
- Unresectable Gastrointestinal Stromal Tumor (GIST), Locally Advanced Gastrointestinal Stromal Tumor (GIST), Metastatic Gastrointestinal Stromal Tumor
- Trial name
- ATEZOGIST (NCT05152472)
- Testing
- Atezolizumab 1200 mg, Imatinib 400 MG
- Where
- 13 sites in France
- Volunteers
- 58 people
- Sponsor
- Centre Leon Berard
Breast Cancer
Combination Chemotherapy in Treating Older Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Trial name
- NCT00010075
- Testing
- fluorouracil, leucovorin calcium, mitoxantrone hydrochloride
- Where
- 6 sites in France
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Survival
Retrospective Analysis of De-identified Deceased HCC Patients
De-identified deceased HCC patients who were not surgical candidates were evaluated for their clinical baseline characteristics associated with their survival.
- Trial name
- NCT04477720
- Volunteers
- 1,000 people
- Sponsor
- Carr, Brian
Breast Cancer, Lymphoma
Adolescent and Young Adult Cancer Patients: Cognitive Toxicity on Survivorship (ACTS)
This study aims to evaluate the prevalence, biological mechanism and survivorship impact of cognitive toxicity among adolescent and young adult (AYA) patients diagnosed with curable cancers.
- Conditions
- Breast Cancer, Lymphoma, Germ Cell Tumor, Cognitive Impairment
- Trial name
- NCT03476070
- Where
- 3 sites in Singapore
- Volunteers
- 236 people, healthy volunteers welcome
- Sponsor
- National University of Singapore
Pancreatic Neoplasm
CROSSFIRE Trial: Comparing the Efficacy of Irreversible Electroporation With Radiotherapy
Irreversible electroporation (IRE) is a promising new ablation technique to fight pancreatic cancer. The primary aim of the CROSSFIRE trial is to compare the efficacy (in terms of overall survival) of FOLFIRINOX and IRE…
- Trial name
- CROSSFIRE (NCT02791503)
- Testing
- Irreversible electroporation (IRE), Stereotactic ablative radiotherapy (SABR)
- Where
- Netherlands
- Volunteers
- 74 people
- Sponsor
- Dr. M.R. Meijerink
Chronic Disease, Kidney Transplantation
Testing the Feasibility of a Self-Management Support Program for Patient With Chronic Diseases in Israel
This study explores an intervention to support people in Israel who are living with chronic health conditions such as cancer or after kidney transplantation.
- Conditions
- Chronic Disease, Kidney Transplantation, Cancer Survivorship
- Trial name
- CDSMP-IL (NCT07367750)
- Testing
- Chronic Disease Self-Management Program (CDSMP)
- Where
- Israel
- Volunteers
- 45 people
- Sponsor
- University of Haifa
Ovarian Cancer (Epithelial)
The Efficacy of Involved-field Radiation Therapy for Residual or Locoregionally Recurrent Epithelial Ovarian Cancer After Definitive Treatment; Multi-institutional Clinical Trial
1. Title: The efficacy of involved-field radiation therapy for residual or locoregionally recurrent epithelial ovarian cancer after definitive treatment; Multi-institutional phase 2 clinical trial 2.
- Trial name
- NCT02135523
- Testing
- involved-field radiation therapy
- Where
- South Korea
- Volunteers
- 26 people
- Sponsor
- Yonsei University
Oral Cancer
Clinical and Molecular Features of Oral Premalignancy and Oral Cancer
Investigators will employ serial assessments of tissue biopsy and additional biomarkers that reflect burden of disease and predict treatment response.
- Trial name
- NCT06550050
- Testing
- Radiation
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- M.D. Anderson Cancer Center
Carcinomas of the Esophagogastric Junction
Esophagogastrectomy Versus Extended Gastrectomy in AEG II
Comparison of the oncological outcome of patients who underwent esophagogastrectomy versus extended gastrectomy due to carcinomas of the esophagogastric junction (Siewert type II)
- Trial name
- AEG-II-EG (NCT02302118)
- Testing
- Esophagogastrectomy
- Where
- Germany
- Volunteers
- 128 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Breast Carcinoma
Demographic , Clinicopathological Characteristics and Survival of Breast Cancer
The investigators will retrospectively study the demographic , clinicopathological characteristics and survival of breast cancer patients admitted to Assiut University hospital from the year 2015 to 2019
- Trial name
- NCT04316247
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assiut University
Head and Neck Cancer, Esophageal Cancer Stage
Outcomes of A Novel Treatment Decision of Patients With Esophageal and Head and Neck Carcinoma Synchronously
To summarise the outcomes of a treatment decision of patients with superficial esophageal carcinoma synchronously associated with head and neck cancer, that is endoscopic treatment for the superficial esophageal carcinoma plus…
- Trial name
- NCT03450447
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Yanqing Li
Adrenal Gland Metastases, Adrenalectomy
Adrenalectomy for Solitary Adrenal Gland Metastases
The adrenal glands are one of the most common organs involved in metastatic disease. Metastases are the second most common type of adrenal mass, second only to adenomas.
- Trial name
- NCT01135238
- Volunteers
- 168 people
- Sponsor
- Mayo Clinic
Multiple Myeloma, Minimal Residual Disease
A Perspective Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial Treatment
The aim of this study was to observe the rate of MRD conversion and the impact on survival in newly diagnosed multiple myeloma (NDMM) patients with persistent MRD positivity after induction and consolidation therapy (autologous…
- Trial name
- MRD (NCT06109233)
- Where
- China
- Volunteers
- 80 people
- Sponsor
- FengYan Jin
Neoplasms, Blood Cancer
Take the Reins: The Effects of Nutrient Timing on Cancer-related Fatigue
Cancer-related fatigue affects at least 30-90% of patients with cancer, depending on the type of cancer and their treatment(s) (e.g., chemotherapy, radiation).
- Conditions
- Neoplasms, Blood Cancer, Fatigue, Diet Habit
- Trial name
- NCT06482515
- Testing
- Time-restricted eating, Nutrition counseling
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- University of Maryland, Baltimore
CLL / SLL, CLL (Chronic Lymphocytic Leukemia)
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
This is a Phase 3, randomized, open-label, multicenter study comparing rocbrutinib (LP-168) versus pirtobrutinib in adult participants with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma…
- Conditions
- CLL / SLL, CLL (Chronic Lymphocytic Leukemia), CLL, Refractory, CLL, Relapsed
- Trial name
- NCT07342478
- Testing
- Rocbrutinib, Pirtobrutinib
- Where
- 6 sites in United States
- Volunteers
- 306 people
- Sponsor
- Newave Pharmaceutical Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.